<DOC>
	<DOCNO>NCT02057718</DOCNO>
	<brief_summary>This open label study child Progressive Familial Intrahepatic Cholestasis ( PFIC ) design evaluate safety efficacy LUM001 . Efficacy assess evaluate effect LUM001 biochemical marker pruritus associate PFIC .</brief_summary>
	<brief_title>Open Label Study Evaluate Efficacy Long Term Safety LUM001 Treatment Cholestatic Liver Disease Patients With Progressive Familial Intrahepatic Cholestasis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<criteria>1 . Male female subject age 12 month 18 year inclusive . 2 . Diagnosis PFIC base : ( ) Intrahepatic cholestasis manifest total serum bile acid &gt; 3x upper limit normal age ; , b c : ( b ) Two document mutant allele ATP8B1 , ABCB11 ; ( c ) Evidence chronic liver disease 3 . GGTP &lt; 100 IU/L screening . 4 . Females childbearing potential must negative urine serum pregnancy test screen negative urine pregnancy test Baseline ( Day 0 ) visit . 5 . Sexually active potentially active male female childbearing potential must prepare use effective method ( ) contraception period study 30 day follow last dose study drug . 6 . Access phone schedule call study site . 7 . Caregivers child age assent must ability read understand one follow language : English , Spanish , US Spanish , French , German Polish . 8 . Subjects expect consistent caregiver ( ) duration first 13 week study . 9 . Caregivers ( age appropriate subject ) must willing able use eDiary device require study , must digitally accespt licensing agreement . 10 . Caregivers ( age appropriate subject ) must complete least 10 eDiary report ( morning even ) two consecutive week screen period , prior assignment ( maximum possible report = 14 per week ) . 1 . Chronic diarrhea require specific intravenous fluid nutritional intervention diarrhea and/or sequela . 2 . Surgical disruption enterohepatic circulation time screen . Subjects undergone reversal prior surgical procedure intend disrupt enterohepatic circulation permanently restore flow bile acid liver terminal ileum may eligible study upon consultation Sponsor Medical Monitor . 3 . Liver transplant . 4 . Decompensated cirrhosis . 5 . ALT &gt; 15 x ULN screen . 6 . History presence liver disease . 7 . History presence disease condition know interfere absorption , distribution , metabolism excretion drug , include bile salt metabolism intestine ( e.g. , inflammatory bowel disease ) . 8 . Liver mass imaging . 9 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 10 . Cancers except situ carcinoma , cancer treat least 5 year prior screen evidence recurrence . 11 . Any female pregnant lactate plan become pregnant within 20 week assignment . 12 . Any known history alcohol substance abuse . 13 . Administration bile acid lipid binding resin within 30 day prior Baseline / Day 0 throughout trial . 14 . Administration sodium phenylbutyrate within 30 day prior Baseline / Day 0 throughout trial . 15 . Investigational drug , biologic , medical device within 30 day prior screen , 5 halflives study agent , whichever longer . 16 . History nonadherence medical regimen , unreliability , mental instability incompetence could compromise validity inform consent lead nonadherence study protocol base Investigator judgment . 17 . Any condition abnormality , opinion Investigator Sponsor Medical Monitor , may compromise safety subject , interfere subject participate completing study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>